We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.05 | 1.52% | 70.01 | 69.50 | 70.00 | 71.09 | 69.65 | 69.93 | 7,916,356 | 01:00:00 |
From Feb 2023 to Feb 2025
1516 EST -- AstraZeneca is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. AstraZeneca is pushing further into vaccines with a cash deal to buy respiratory specialist Icosavax for about $1.1 billion. Icosavax is developing a potential vaccine, called IVX-A12, for two common respiratory diseases that are leading causes of respiratory infection and hospitalization among adults 60 years of age and older: respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Deals in the red-hot biotech and pharmaceutical space have heated up into the end of the year, boding well for momentum into 2024. Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com)
(END) Dow Jones Newswires
December 12, 2023 15:31 ET (20:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
